Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
Create a narrative
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Alphabet
BL
BlackGoat
Community Contributor
Alphabet: The Under-appreciated Compounder Hiding in Plain Sight
Summary Google trades at ~18× forward earnings; the cheapest among the Magnificent 7 Market is too focused on AI threats to Search and antitrust noise Meanwhile, Google is executing across AI, Cloud, and YouTube Key AI differentiator: unmatched distribution across 3B+ users via Search, Gmail, YouTube, Android, Chrome, and Cloud Quietly building a world-class AI infrastructure behind the scenes; including proprietary TPUs and a vertically integrated stack YouTube generated $8.93B in Q1 ad revenue (up 10% YoY); subscriptions hit 270M Google Cloud revenue up 28% YoY to $12.3B; now profitable Optionality from long-term bets like Waymo, DeepMind, and Verily Risk/reward is compelling; a strong candidate to beat the market long term Overview Despite being part of the "Magnificent Seven," Google’s stock lags due to perceived risks around disruption of its Search business from AI competitors and mounting antitrust concerns. But under the hood, Google has quietly built one of the most compelling setups in tech: with deep AI leadership, multiple high-growth businesses, and optionality from long-term moonshots like Waymo.
View narrative
US$282.83
FV
30.8% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
24
users have liked this narrative
3
users have commented on this narrative
63
users have followed this narrative
Updated
narrative
Planet Labs PBC
AN
andreas_eliades
Community Contributor
Planet Labs: At The Heart Of The Emerging New Space Boom
Planet Labs leads the EO market with the largest satellite constellation, poised to capitalize on the growing demand for Earth Observation and geospatial data from companies and governments. Plunging space launch and GPU computation costs combined with advancements in CubeSat and AI technologies are boosting the utility of Earth Observation data.
View narrative
US$11.31
FV
42.2% undervalued
intrinsic discount
30.00%
Revenue growth p.a.
Set Fair Value
18
users have liked this narrative
1
users have commented on this narrative
68
users have followed this narrative
New
narrative
Exxon Mobil
AG
Agricola
Community Contributor
Exxon in Guyana 5 year forecast Low $135 to High $189
Previous mistake rectified. So as pointed out in the comments, Chevron won the Hess bid (rather than Exxon) and took a large portion of the Stabroek block.
View narrative
US$174.00
FV
38.3% undervalued
intrinsic discount
12.97%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
4
users have commented on this narrative
18
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
TCI Express
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
Expanding Air Express And Multimodal Services Will Boost Customer Reach And Service Levels
Key Takeaways Expansion of delivery networks and multimodal services aims to diversify revenue streams and improve margins through higher-margin offerings. Investments in automation and IT infrastructure, supported by government initiatives, are set to enhance operational efficiency and reduce costs.
View narrative
₹838.45
FV
18.5% undervalued
intrinsic discount
7.92%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
5 days ago
author updated this narrative
Verve Group
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
ID-less Targeting And AI Investments Will Drive Future Success In Privacy-Focused Advertising
Key Takeaways Verve Group's ID-less targeting solutions and expansion into digital channels position it for revenue growth in a privacy-focused advertising market. Integration of Jun Group and investment in AI-driven solutions are expected to improve operational efficiencies and enhance net margins.
View narrative
€6.22
FV
56.6% undervalued
intrinsic discount
11.69%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
8
users have followed this narrative
5 days ago
author updated this narrative
Pharma Mar
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
Key Takeaways Successful approval of ZEPZELCA in Europe and new markets could significantly boost PharmaMar’s future revenues, leveraging positive trial results. PharmaMar's strong cash position and robust pipeline support reinvestment and potential long-term revenue growth, with a stable cost structure enhancing margins.
View narrative
€104.60
FV
24.1% undervalued
intrinsic discount
40.35%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
18
users have followed this narrative
5 days ago
author updated this narrative
Sea1 Offshore
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Viking Deals And Offshore Builds Will Boost Fleet Amid Risks
Key Takeaways Revenue growth is anticipated through new agreements, vessel expansions, and positive market forecasts in the subsea vessel segment. Strong contract backlog and asset sales contribute to stable cash flows and enhanced profitability.
View narrative
NOK 30.90
FV
13.6% undervalued
intrinsic discount
-5.11%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
5 days ago
author updated this narrative
Novartis
AN
AnalystConsensusTarget
Consensus Narrative from 18 Analysts
China Expansion And Advanced Therapies Will Drive Future Upside
Key Takeaways Strong demand for innovative therapies and expansion in emerging markets support growth, while operational efficiency boosts margins and long-term profitability. Advancements in advanced therapies and substantial shareholder returns position the company for accelerated earnings and enhanced equity performance.
View narrative
CHF 98.85
FV
4.3% undervalued
intrinsic discount
2.22%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
82
users have followed this narrative
5 days ago
author updated this narrative
Union Bank of the Philippines
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Completion Of Citi Integration Will Enable Focus On Growth Initiatives By 2025
Key Takeaways Focus on consumer loans and strategic shifts aim to sustain high net interest margins, enhancing future revenue growth and profitability. Improved operational efficiency and increasing non-interest income from transaction services are expected to enhance earnings quality and net margins.
View narrative
₱42.58
FV
25.3% undervalued
intrinsic discount
24.42%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
45
users have followed this narrative
5 days ago
author updated this narrative
ZAG
Zumtobel Group
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Recovery In Non-Residential Construction And New Products Will Improve Future Prospects
Key Takeaways Strategic focus on renovation and maintenance, along with new product introductions, positions for recovery in non-residential construction, boosting future revenue and margins. Long-term contracts and key accounts provide revenue stability and visibility, mitigating demand volatility and potentially improving earnings.
View narrative
€5.10
FV
13.1% undervalued
intrinsic discount
1.13%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
5 days ago
author updated this narrative
Strides Pharma Science
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Affordable Generics And Digital Trends Will Broaden Global Healthcare Reach
Key Takeaways Expansion in high-value generics, R&D investments, and digital transformation are driving diversified growth and long-term profitability across regulated and emerging markets. Streamlined product portfolio, cost optimization, and supply chain efficiencies are boosting margins and supporting sustainable earnings improvement.
View narrative
₹1.08k
FV
22.3% undervalued
intrinsic discount
12.93%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
5 days ago
author updated this narrative
Metropolis Healthcare
AN
AnalystConsensusTarget
Consensus Narrative from 19 Analysts
Integration Of Core Diagnostics Will Strengthen Specialty Diagnostics Leadership
Key Takeaways Strategic acquisitions and high-tech expansions are expected to drive Metropolis' revenue growth and enhance specialty diagnostics leadership. Investment in technology and micro marketing strategies is set to improve patient engagement, operational efficiency, and optimize future revenue generation.
View narrative
₹1.94k
FV
5.4% overvalued
intrinsic discount
15.77%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
5 days ago
author updated this narrative
Value any company in seconds
Popular companies